PMID- 38525371
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240326
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 16
DP  - 2024
TI  - Efficacy and Safety of Maintenance Therapy Using Cetuximab in Patients with 
      Metastatic Colorectal Cancer: Retrospective Study.
PG  - 185-197
LID - 10.2147/CMAR.S443666 [doi]
AB  - PURPOSE: Cetuximab (CET) combined with chemotherapy significantly improved the 
      survival in RAS and RAF wild-type metastatic colorectal cancer (mCRC) patients, 
      while clinical evidence was lacking on the use of maintenance therapy (MT). The 
      study aimed to explore the role of maintenance therapy following Cetuximab + 
      chemotherapy and the optimal Cetuximab-based maintenance therapy regimen. 
      PATIENTS AND METHODS: We retrospectively reviewed data on the efficacy and safety 
      of CET-based MT in patients with mCRC who achieved disease control after 
      induction therapy. RESULTS: Eighty-one patients with mCRC who achieved disease 
      control after CET + chemotherapy induction were enrolled. Overall median 
      progression-free survival (PFS) was 10.5 (95% CI = 8.8-12.2) months and median 
      maintenance/observation PFS (mnPFS) was 6.0 (95% CI = 5.0-7.0) months. Among 
      these 81 patients, 61 patients were prescribed MT (CET alone for 21 patients and 
      CET + chemotherapy for 40 patients). Median PFS and mnPFS in the MT group were 
      significantly longer than those for the non-MT group. Different MT regimens did 
      not affect PFS and mnPFS significantly. Univariate and multivariate analysis 
      demonstrated MT, complete response/partial response during induction therapy, and 
      absence of peritoneal metastasis to be positively associated with longer PFS and 
      mnPFS. Treatment-related adverse events (AEs) were tolerable during MT, and 
      AE-related deaths were not observed. CONCLUSION: MT with CET or CET + 
      chemotherapy was an appropriate option following initial induction chemotherapy 
      for patients with RAS and RAF wild-type mCRC. This strategy endowed survival 
      benefits and a tolerable safety profile.
CI  - (c) 2024 Xuan et al.
FAU - Xuan, Tiantian
AU  - Xuan T
AD  - Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of 
      Medicine, Shandong University, Qingdao, Shandong, People's Republic of China.
FAU - Wang, Zhanmei
AU  - Wang Z
AD  - Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of 
      Medicine, Shandong University, Qingdao, Shandong, People's Republic of China.
FAU - Meng, Sibo
AU  - Meng S
AUID- ORCID: 0000-0003-1861-496X
AD  - Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of 
      Medicine, Shandong University, Qingdao, Shandong, People's Republic of China.
FAU - Li, Jiaxin
AU  - Li J
AD  - Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of 
      Medicine, Shandong University, Qingdao, Shandong, People's Republic of China.
FAU - Li, Jisheng
AU  - Li J
AD  - Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, Shandong, People's Republic of China.
FAU - Cao, Fangli
AU  - Cao F
AD  - Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of 
      Medicine, Shandong University, Qingdao, Shandong, People's Republic of China.
FAU - Qu, Linli
AU  - Qu L
AD  - Department of Medical Oncology, Qilu Hospital (Qingdao), Cheeloo College of 
      Medicine, Shandong University, Qingdao, Shandong, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20240319
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC10960546
OTO - NOTNLM
OT  - RAS and RAF wild-type
OT  - cetuximab
OT  - colorectal cancer
OT  - maintenance therapy
OT  - targeted therapy
COIS- The authors report no conflicts of interest in this work.
EDAT- 2024/03/25 06:43
MHDA- 2024/03/25 06:44
PMCR- 2024/03/19
CRDT- 2024/03/25 04:41
PHST- 2023/10/09 00:00 [received]
PHST- 2024/02/28 00:00 [accepted]
PHST- 2024/03/25 06:44 [medline]
PHST- 2024/03/25 06:43 [pubmed]
PHST- 2024/03/25 04:41 [entrez]
PHST- 2024/03/19 00:00 [pmc-release]
AID - 443666 [pii]
AID - 10.2147/CMAR.S443666 [doi]
PST - epublish
SO  - Cancer Manag Res. 2024 Mar 19;16:185-197. doi: 10.2147/CMAR.S443666. eCollection 
      2024.